Experienced in Legius Syndrome

Dr. David L. Fried

Coastal Medical Physicians Inc
East Greenwich, RI
Experienced
in Legius Syndrome
Specialties:Internal Medicine
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

David Fried is an Internal Medicine provider in East Greenwich, Rhode Island. Dr. Fried and is rated as an Experienced provider by MediFind in the treatment of Legius Syndrome. His top areas of expertise are Migraine with Brainstem Aura, Familial Hemiplegic Migraine, Familial Hypertension, and Glucocorticoid-Remediable Aldosteronism.

His clinical research consists of co-authoring 4 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Internal Medicine
Licenses
Internal Medicine in RI
Hospital Affiliations
Rhode Island Hospital
Kent County Memorial Hospital
The Miriam Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Tufts
  •  Cigna
  •  Blue Cross Blue Shield
  •  Aetna
  •  UnitedHealthcare
  •  Humana

Locations

COASTAL MEDICAL PHYSICIANS INC
1598 S County Trl, Suite 201, East Greenwich, RI 02818
401-884-0333

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
Enrollment Status: Completed
Publish Date: August 30, 2024
Intervention Type: Biological
Study Phase: Phase 3
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Enrollment Status: Completed
Publish Date: August 01, 2024
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Phase 1/2, Randomized, Observer-Blind, Dose-Finding, Controlled, Parallel-Group, Two-Stage Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Adults Aged 18 to 64 Years
A Phase 1/2, Randomized, Observer-Blind, Dose-Finding, Controlled, Parallel-Group, Two-Stage Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Adults Aged 18 to 64 Years
Enrollment Status: Completed
Publish Date: April 18, 2024
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)
Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)
Enrollment Status: Completed
Publish Date: April 08, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Biological, Other
Study Drug: SARS-CoV-2 rS/Matrix-M1 Adjuvant
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: November 27, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Multicenter Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of a Freeze-dried Formulation of MVA-BN® Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects
A Randomized, Double-blind, Multicenter Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of a Freeze-dried Formulation of MVA-BN® Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Biological
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Enrollment Status: Completed
Publish Date: November 20, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase IIa Randomized, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Bimatoprost in the Treatment of Migraine
A Phase IIa Randomized, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Bimatoprost in the Treatment of Migraine
Enrollment Status: Unknown
Publish Date: April 26, 2019
Intervention Type: Drug
Study Drug: Bimatoprost Topical Solution
Study Phase: Phase 2
View 10 Less Clinical Trials
Similar Doctors
Expertise in
3
conditions
Dr. Richard C. Mcmahon
Internal Medicine
Expertise in
3
conditions
Dr. Richard C. Mcmahon
Internal Medicine

Charles River Medical Associates, PC

101 Coolidge St, 
Hudson, MA 
 (51.9 mi)
978-562-0763
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Richard Mcmahon is an Internal Medicine provider in Hudson, Massachusetts. Dr. Mcmahon and is rated as an Advanced provider by MediFind in the treatment of Legius Syndrome. His top areas of expertise are Neurofibromatosis, Legius Syndrome, RASopathies, and Infant Hyperglycemia. Dr. Mcmahon is currently accepting new patients.

Expertise in
0
conditions
Dr. Nivedita Gour
Internal Medicine
Expertise in
0
conditions
Dr. Nivedita Gour
Internal Medicine

Umass Memorial Medical Group Inc

55 Lake Ave N, 
Worcester, MA 
 (45.5 mi)
508-334-1000
Experience:
26+ years
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Nivedita Gour is an Internal Medicine provider in Worcester, Massachusetts. Dr. Gour has been practicing medicine for over 26 years and is rated as an Experienced provider by MediFind in the treatment of Legius Syndrome. Her top areas of expertise are Premature Ovarian Failure, Infertility, Vertigo, and Fainting. Dr. Gour is currently accepting new patients.

Expertise in
0
conditions
Dr. Yan C. Li
Internal Medicine
Expertise in
0
conditions
Dr. Yan C. Li
Internal Medicine

Umass Memorial Medical Group Inc

55 Lake Ave N, 
Worcester, MA 
 (45.5 mi)
508-334-1000
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Yan Li is an Internal Medicine provider in Worcester, Massachusetts. Dr. Li and is rated as an Experienced provider by MediFind in the treatment of Legius Syndrome. Her top areas of expertise are Vertigo, Chronic Cough, Sitosterolemia, and Familial Hypertension. Dr. Li is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile